WA-KYMETA
10.3.2020 13:02:17 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com )—the communications company making mobile global—announced the commercial availability of its next generation flat panel electronically steered antenna platform, the Kymeta u8. The new u8 terminal paired with Kymeta’s hybrid satellite-cellular connectivity services transforms the purchase and consumption of mobile data with an all-inclusive hardware, connectivity and services monthly subscription starting at $999. The Kymeta u8 is the world’s only commercially available flat panel electronically steered antenna built specifically for mobility and designed for the needs of both military and commercial customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005297/en/
The Kymeta u8 antenna enables complete coverage of the Ku-band with highly reliable electronic beam steering and no moving parts. It is available as an antenna, as a terminal, or in flyaway configurations, and it can be paired with Kymeta’s new satellite and hybrid satellite-cellular connectivity solutions.
Powered by top satellite service and cellular operators throughout the world, Kymeta Connect makes buying hardware, connectivity, network services, and global support as simple and predictable as buying a mobile phone plan. A variety of satellite or satellite-cellular airtime packages are available and provided in partnership with Intelsat and Cubic Telecom, among others. Customers will now have access to easily deployable and dependable mobile connectivity in places where reliable and affordable connectivity has not been available. Kymeta is also working with LEO satellite operators on technology and service collaborations as described in press announcements released during Satellite 2020.
“With our new u8 terminal paired with Kymeta Broadband connectivity and support, we are making mobile global with a fully managed, optimized, and easy to use blended service,” said Walter Berger, President and Chief Operating Officer, Kymeta. “It is a complete solution with an elegant simplicity that will be very attractive to companies who need predictable OPEX pricing for their regional mobile connectivity services. We believe this is an industry tipping point for unlocking new access to the internet in all parts of the world.”
“We look forward to expanding our successful partnership with Kymeta as they add Intelsat’s FlexMove managed service to their communications-on-the-move (COTM) connectivity solutions offerings. Working together, Kymeta and Intelsat are helping people stay connected wherever they need to be, no matter how remote or challenging the location,” said Samer Halawi, Chief Commercial Officer, Intelsat.
Kymeta’s mobile connectivity services will be available in the US, Europe, the Middle East, Asia Pacific, sub-Saharan Africa, and Oceania with services extending to future geographies in the coming months. Initial deployments will include the military, first responders, buses, vehicle fleets, small maritime vessels, ferries, trucks and trains.
Show attendees can sign up for a meeting or live driving demonstration of the Kymeta u8 by emailing marketing@Kymetacorp.com . Additionally, the Kymeta u8 video is live and available to watch at www.kymetacorp.com .
About Kymeta
Kymeta is unlocking the potential of satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for mobile connectivity. The company’s flat-panel satellite antenna, the first of its kind, and Kymeta™ Connect connectivity services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom